| Date | Title | Description |
| 31.08.2022 | The Impact of a Rapid Blood Culture Identification System on a Pediatric Institution, Upcoming Webinar Hosted by Xtalks | Pediatric blood cultures present unique problems such as fastidious organisms, antimicrobial treatment and small specimen volumes.
TORONTO (PRWEB) August 31, 2022
Although automated blood systems can save time, subcultures are required for ... |
| 28.02.2022 | Rapid BCID Saved Costs and Reduced Healthcare Worker-Patient Interaction Time During the COVID-19 Pandemic, Upcoming Webinar Hosted by Xtalks | The featured speaker will discuss how the BCID panels helped to reduce healthcare worker time and increased their safety during the COVID-19 pandemic.
TORONTO (PRWEB) February 28, 2022
Throughout the COVID-19 pandemic, healthcare workers ac... |
| 17.05.2021 | Navigating the Choppy Waters of Implementing Rapid Molecular Blood Culture Identification Tests, Upcoming Webinar Hosted by Xtalks | For any new test, there are several factors to consider both on the laboratory and the stewardship side.
TORONTO (PRWEB) May 17, 2021
The implementation process for rapid molecular blood culture identification can be a complex process for l... |
| 15.03.2021 | Roche’s $1.8B GenMark deal brings a key testing capability for Covid-19 and beyond | According to financial terms announced Monday, Switzerland-based Roche will pay $24.05 cash for each GenMark share. That price represents a more than 30% premium to the company’s closing stock price on Friday. It’s a 43% premium to the stoc... |
| 01.02.2021 | The Big Picture of Rapid Blood Culture ID: A Retrospective Clinical Analysis Building to a Prospective Clinical Trial, Upcoming Webinar Hosted by Xtalks | The two studies being showcased in this webinar will provide a big-picture view of how the ePlex BCID Panels are improving rapid blood culture diagnostics.
TORONTO, Ontario (PRWEB) February 01, 2021
In this webinar, Dr. Yvan Caspar from Gre... |
| - | Roche’s $1.8B GenMark deal brings a key testing capability for Covid-19 and beyond | Roche is adding to its diagnostic capabilities through a deal to acquire GenMark Diagnostics, a molecular diagnostics company whose technology tests for multiple pathogens—including the novel coronavirus—from a single patient sample.
Accord... |
